Crescendo Biologics

Last updated: October 10, 2024

Peter Pack, CEO
Peter Pack, CEO
UK | Funding: $148.2M (+)

Website: https://www.crescendobiologics.com/

Crescendo has developed a novel bispecific T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment